曲美他嗪联合依那普利治疗心力衰竭的临床分析

Clinical Analysis of Trimetazidine Combined with Enalapril in the Treatment of Heart Failure

目的探讨曲美他嗪联合依那普利治疗心力衰竭的临床疗效与安全性。方法方便选取2014年6月—2017年6月该院137例心力衰竭患者为研究对象,依据治疗方法不同分为实验组(心衰规范治疗+曲美他嗪,69例)和对照组(心衰规范治疗,68例),对比观察两组疗效。结果实验组治疗总有效率(88.41%)高于对照组,LVEF(45.1±6.2)%,再住院率17.39%,各项指标均优于对照组,差异有统计学意义(χ2=4.376,t=4.826,χ2=5.831,P<0.05)。结论曲美他嗪联合依那普利治疗心力衰竭效果确切,可有效改善患者临床症状,提高运动耐力,减少再住院率,但不能降低主要终点事件。

Objective To investigate the clinical efficacy and safety of trimetazidine combined with enalapril in the treatment of heart failure.Methods From June 2014 to June 2017,137 patients with heart failure in the hospital were convenient selected and studied.According to different treatment methods,they were divided into experimental group (standard treatment of heart failure + trimetazidine,69 cases) and control group (heart failure standardized treatment,68 cases),comparative observation of the efficacy of the two groups.Results The total effective rate of the experimental group (88.41%) was higher than that of the control group,LVEF (45.1±6.2)%,and the rehospitalization rate was 17.39%.All the indexes were better than the control group,the difference was statistically significant (χ^2=4.376,t=4.826,χ^2= 5.831,P<0.05).Conclusion Trimetazidine combined with enalapril is effective in the treatment of heart failure,which can effectively improve the clinical symptoms,improve exercise endurance and reduce the rate of rehospitalization,but can not reduce the main endpoint events.